FP6 project “CARCINOGENOMICS” started in November
Its major aim is to develop in vitro methods for testing the carcinogenic properties of compounds as an alternative to the chronic rodent bioassays for assessing chemical genotoxicity and carcinogenicity. The major goal is to develop a battery of mechanism-based in vitro tests representative for various modes of carcinogenic action, in lungs, liver and kidney. It is expected that the outcome of this project will generate a platform enabling the investigation of large numbers of compounds for their genotoxic and carcinogenic potential. This will contribute to speeding up the process of identifying potential harmful substances to man, while lowering costs and reducing animal tests. Thus, the CARCINOGENOMICS project will have a measurable and verifiable impact on testing needs as identified under REACH. The CARCINOGENOMICS project represents a highly innovative approach possibly leading to in silico (computer-based) models that may be used to predict the carcinogenic potential of a compound in vivo. A critical mass of twenty of the leading European investigators in these areas of toxicogenomics research has been brought together in this Integrated Project. Total funding by the EU amounts to € 10,440,000 over the 5-year-period of active research. CARCINOGENOMICS is a 6th Framework Programme funded by the EU, Project Number: 037712 For information, please refer to the Project Manager R. Reijnders at Maastricht University (RJHM Reijnders MSc | Projectmanager Maastricht University, GRAT, PO Box 616, 6200MD Maastricht Tel.: +31 (0) 43-3881845 | Fax: +31 (0) 43-3884146 | Email: r.reijnders@grat.unimaas.nl) Future website: www.carcinogenomics.ecopa.eu Status: November 2006
Countries
Austria, Belgium, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Poland, Portugal, Sweden, Slovenia, Slovakia, United Kingdom